Attorney Docket No. 49674 CPA (72024)
Serial No. 09/537,858
Piled: March 28, 2000
Amendment and Response to [Non-Final/Final] Office Action dated January 15, 2004
Page 2 of 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claims 1-23 are cancelled.

- Claim 24. (Previously Added). An isolated amino-terminally truncated RANTES polypeptide comprising residues 2-68 of a RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residue 1 and has chemokine antagonistic activity.
- Claim 25. (Previously Added) An isolated amino-terminally truncated RANTES polypeptide comprising residues 3-68 of a RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 and has chemokine antagonistic activity.
- Claim 26. (Previously Added) An isolated amino-terminally truncated RANTES comprising residues 4-68 of a RANTES polypeptide according to RANTES (SEQ ID NO: 2), wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
- Claim 27. (Previously Added) An isolated amino-terminally truncated RANTES comprising residues 5-68 of an RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NII<sub>2</sub>-terminal amino acid residues 1-4 and has chemokine antagonistic activity.

Attorney Docket No. 49674 CPA (72024)
Scrial No. 09/537,858
Filed: March 28, 2000
Amendment and Response to [Non-Final/Final] Office Action dated January 15, 2004
Page 3 of 3

- Claim 28. (Currently Amended) The isolated amino-terminally truncated RANTES of claims 24-27 [26-29], wherein the truncated RANTES polypeptide is in glycosylated form.
- Claim 29. (Currently Amended) A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to any one of claims <u>24-27</u> [25-29], wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.
- Claim 30. (Currently Amended) The pharmaceutical composition according to claim 29 [31], wherein the isolated truncated RANTES polypeptide is in glycosylated form.

## CONCLUSION

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Respectfully submitted,

Date: 2/15/2004

Dianne M. Rees, Ph.D.

Reg. No. 45,281

EDWARDS & ANGELL, LLP

P.O. Box 55874 Boston, MA 02205

Telephone: 617-439-4444 Customer No. 21874

BO\$2 ,434237.1